CoQ10 in Huntington’s study
This article was originally published in The Tan Sheet
Executive Summary
The effect of coenzyme Q10 on cognitive function in Huntington's disease patients will be tested in a phase III clinical trial by the Huntington Study Group, according to a June 2 release. The five-year study will measure the maximum effective dosage of CoQ10 for treating Huntington's, a genetic, progressive brain disorder with no known cure or proven drug therapy. Pasadena, Texas-based Kaneka Nutrients will supply the supplement for the trial. In addition to its documented neurological benefits, CoQ10 has cardio health advantages pharmaceutical developers are attempting to harness (1"The Tan Sheet" June 2, 2008, p. 8)...
You may also be interested in...
Dietary Supplements Blossom As Revenue Growth Ingredients For Big Pharma
Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: